Spero Therapeutics financials
$1.20+0.84%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $258.0K | $41.3M | $5.4M | $14.2M | $5.9M | $15.0M | $13.5M | $10.2M | $9.3M | $73.5M | $25.5M |
| Gross profit | $0.00 | $258.0K | $41.3M | $5.4M | $14.2M | $5.9M | $15.0M | $13.5M | $10.2M | $9.3M | $73.5M | $25.5M |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$9.9M | -$7.5M | $31.4M | -$7.9M | -$2.4M | -$14.7M | -$21.7M | -$18.6M | -$19.1M | -$14.0M | $55.8M | -$1.9M |
| Net income | -$9.6M | -$7.2M | $31.5M | -$7.4M | -$1.7M | -$13.9M | -$20.9M | -$17.1M | -$17.9M | -$12.7M | $51.2M | -$3.2M |
| Net margin | — | −2791.9% | 76.3% | −135.6% | −12.0% | −236.1% | −138.8% | −127.3% | −175.2% | −136.7% | 69.6% | −12.6% |
| Diluted EPS | $-0.16 | $-0.13 | $0.46 | $-0.13 | $-0.03 | $-0.25 | $-0.38 | $-0.32 | $-0.33 | $-0.24 | $0.95 | $-0.06 |
| EBITDA | -$9.9M | -$7.5M | $31.4M | -$7.3M | -$2.4M | -$14.6M | -$20.8M | -$18.6M | -$19.1M | -$14.0M | $50.6M | $3.5M |
| Operating cash flow | -$5.4M | $15.9M | -$8.4M | $17.4M | -$17.7M | -$4.0M | -$23.4M | $12.8M | -$18.7M | $5.9M | -$17.5M | $15.9M |
| Free cash flow | -$5.4M | $15.9M | -$8.4M | $17.4M | -$17.7M | -$4.0M | -$23.4M | $12.8M | -$18.7M | $5.9M | -$17.5M | $15.9M |
| Diluted shares | 58.0M | 57.3M | 68.5M | 56.3M | 56.0M | 55.4M | 54.5M | 54.1M | 54.0M | 53.5M | 54.1M | 52.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $50.8M | $56.1M | $40.3M | $48.6M | $31.2M | $48.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $91.0K | $91.0K | $91.0K | $0.00 | $0.00 | $0.00 |
| Total assets | $52.8M | $59.0M | $68.9M | $54.2M | $62.1M | $77.7M |
| Total liabilities | $8.6M | $6.1M | $9.9M | $27.7M | $29.3M | $43.9M |
| Shareholders' equity | $44.2M | $52.9M | $59.0M | $26.5M | $32.8M | $33.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology